2025 Q4 -tulosraportti
26 päivää sitten
‧56 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 226 | - | - | ||
| 206 | - | - | ||
| 44 | - | - | ||
| 31 | - | - | ||
| 6 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 218 287 | 218 287 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 218 287 | 218 287 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 | ||
2025 Q1 -tulosraportti 24.4.2025 | ||
2024 Q4 -tulosraportti 6.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·2 päivää sitten• NovaQuest lock-up: Their 180-day lock-up from the issuance has expired, which means they can now freely sell their shares. • Motive for selling: NovaQuest has reasons to secure its capital, especially since their holding is in profit (subscription price 22 SEK). • Previous choice: In January, NovaQuest chose to receive cash payment instead of shares, which suggests that liquidity may be prioritized. • Market effect: If NovaQuest starts selling, this could push the share price down towards approximately 20 SEK, according to HS Formation. • Recent share sale: A close associate of Hansa Biopharma's board member Michael Bologna, Devin Holden (NovaQuest's compliance manager), has sold 141,000 shares for approximately 5.7 million SEK. Michael Bologna is Investment Manager at Novaquest Capital Management In short: The lock-up period is over, NovaQuest may have reason to sell to prioritize liquidity over ownership, and a recently registered insider sale could signal that more shares may come onto the market, which could negatively affect the price. It's a long wait until December 🕛 and perhaps the company has additional capital needs. My opinion and not advice. https://view.news.eu.nasdaq.com/view?id=b98b852aee40a178912c92e6a60a29fba&lang=sv&src=micro
·3 päivää sitten · MuokattuSomeone probably noticed the missing priority review on February 18th, I would think, when looking at the share price development. But it was not highlighted in the press at the time, so now we will briefly pay twice the share price loss for the delay. But what amount are we talking about in money for today's delayed focus on an "unexpected 4-month delay." 250 mio. SEK - divided by 100 mio. shares. 2.50 SEK per share, if the market doesn't come to its senses and realize that we - knowingly or unknowingly - already paid on February 19th. The amount largely corresponds to what the share often can rise on a good day - and fall on a bad day - without current share-related news. But currently the mood is not high in the stock market.- ·5.3. · MuokattuCapital injection can happen in many ways. For example, through a directed issue, a loan, an affiliation with a partner, or a sale of licenses or an out-licensing of products with upfront milestone payments. The possibilities are many if the product is good, and there is interest in it, and the company has competent management. Fortunately, it absolutely doesn't have to be a rights issue, which usually goes terribly wrong. And Hansa has indeed had good success with directed issues previously. But it's a shame about the delay in any case.
·5.3. · MuokattuFOR THE RECORD: Many believe, quite wrongly, that the FDA review will take 12 months for Standard review, as Hansa Biopharma received for its BLA for imliffidase in kidney transplantation "HighDes). This compared to Priority review, where the review takes 6 months before PDUFA But here there is a misunderstanding among many! "The clock is ticking", i.e., the starting point for the review ("Review"), starts instead after day 60, given that the FDA accepts the BLA application for review. It is from this point that one counts 10 months (Standard review) and 6 months (Priority review) respectively. So 10 months counted from day 60, i.e., as of February 18, 2026, means that we land on a PDUFA-date as of December 19, 2026. Thus, one loses 4 months with Standard review, compared to if one had received Priority review. Not the end of the world, in other words! So a 4-month delay with Standard review ... compared to Priority review, i.e., 10 months of review instead of 6 months of the same ... is not, said again, the end of the world! Regards·3 päivää sitten · MuokattuI don't write on Facebook, but in a discussion forum, where the purpose hopefully is that we can all become wiser. After all, it's about our invested money. So, there will be no further comments on the above's offended reaction. The debate is more important than that, which can be seen, for example, by today's share price reaction and my post above in connection with it: "Need for further financing, you could have written. It's not certain that it has to happen as an emission - and many are scared by the word emission and read it as "rights issue" and think of the catastrophic rights issues one usually experiences - currently, for example, KD-ventures and Expres2ion, so therefore one must be careful with the words. The latest issues in Hansa have, on the contrary, been very good directed issues." Reply More- ·19.2.DNB is really "showing off" today and significantly raises the target price: "DNB Carnegie raises the target price for Hansa Biopharma to 35 kronor (33), reiterates hold" HC Wainwright, however, the other day lowers the target price for Hansa Biopharma to 103 kronor (111), reiterates buy.
·20.2. · MuokattuThere are clearly shorters who are counting on a large capital increase and possibly a delayed or "missed" approval in the USA. HCW then believes that it will continue to run by the book and that we will have a US approval in 2026/2027 - hope HCW is right - otherwise the 2027 ski trip is screwed. Would like to see some kind of deal with something upfront, which could eliminate the risk of a capital increase. Even if it doesn't end with a capital increase, more loans would also be annoying - we need to become CashFlow positive - it's currently probably mostly the enormous burnrate that makes some people uncertain - and that's with good reason.·20.2.Of course, it would be nice if we avoid loans or capital increases, which, of course, take a part of our expected return on our investment. But I don't fear it so much in Hansa, which has good experience with directed issues to external investors. Last time, as far as I remember, at a price of 39.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
26 päivää sitten
‧56 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sitten• NovaQuest lock-up: Their 180-day lock-up from the issuance has expired, which means they can now freely sell their shares. • Motive for selling: NovaQuest has reasons to secure its capital, especially since their holding is in profit (subscription price 22 SEK). • Previous choice: In January, NovaQuest chose to receive cash payment instead of shares, which suggests that liquidity may be prioritized. • Market effect: If NovaQuest starts selling, this could push the share price down towards approximately 20 SEK, according to HS Formation. • Recent share sale: A close associate of Hansa Biopharma's board member Michael Bologna, Devin Holden (NovaQuest's compliance manager), has sold 141,000 shares for approximately 5.7 million SEK. Michael Bologna is Investment Manager at Novaquest Capital Management In short: The lock-up period is over, NovaQuest may have reason to sell to prioritize liquidity over ownership, and a recently registered insider sale could signal that more shares may come onto the market, which could negatively affect the price. It's a long wait until December 🕛 and perhaps the company has additional capital needs. My opinion and not advice. https://view.news.eu.nasdaq.com/view?id=b98b852aee40a178912c92e6a60a29fba&lang=sv&src=micro
- ·3 päivää sitten · MuokattuSomeone probably noticed the missing priority review on February 18th, I would think, when looking at the share price development. But it was not highlighted in the press at the time, so now we will briefly pay twice the share price loss for the delay. But what amount are we talking about in money for today's delayed focus on an "unexpected 4-month delay." 250 mio. SEK - divided by 100 mio. shares. 2.50 SEK per share, if the market doesn't come to its senses and realize that we - knowingly or unknowingly - already paid on February 19th. The amount largely corresponds to what the share often can rise on a good day - and fall on a bad day - without current share-related news. But currently the mood is not high in the stock market.
- ·5.3. · MuokattuCapital injection can happen in many ways. For example, through a directed issue, a loan, an affiliation with a partner, or a sale of licenses or an out-licensing of products with upfront milestone payments. The possibilities are many if the product is good, and there is interest in it, and the company has competent management. Fortunately, it absolutely doesn't have to be a rights issue, which usually goes terribly wrong. And Hansa has indeed had good success with directed issues previously. But it's a shame about the delay in any case.
- ·5.3. · MuokattuFOR THE RECORD: Many believe, quite wrongly, that the FDA review will take 12 months for Standard review, as Hansa Biopharma received for its BLA for imliffidase in kidney transplantation "HighDes). This compared to Priority review, where the review takes 6 months before PDUFA But here there is a misunderstanding among many! "The clock is ticking", i.e., the starting point for the review ("Review"), starts instead after day 60, given that the FDA accepts the BLA application for review. It is from this point that one counts 10 months (Standard review) and 6 months (Priority review) respectively. So 10 months counted from day 60, i.e., as of February 18, 2026, means that we land on a PDUFA-date as of December 19, 2026. Thus, one loses 4 months with Standard review, compared to if one had received Priority review. Not the end of the world, in other words! So a 4-month delay with Standard review ... compared to Priority review, i.e., 10 months of review instead of 6 months of the same ... is not, said again, the end of the world! Regards·3 päivää sitten · MuokattuI don't write on Facebook, but in a discussion forum, where the purpose hopefully is that we can all become wiser. After all, it's about our invested money. So, there will be no further comments on the above's offended reaction. The debate is more important than that, which can be seen, for example, by today's share price reaction and my post above in connection with it: "Need for further financing, you could have written. It's not certain that it has to happen as an emission - and many are scared by the word emission and read it as "rights issue" and think of the catastrophic rights issues one usually experiences - currently, for example, KD-ventures and Expres2ion, so therefore one must be careful with the words. The latest issues in Hansa have, on the contrary, been very good directed issues." Reply More
- ·19.2.DNB is really "showing off" today and significantly raises the target price: "DNB Carnegie raises the target price for Hansa Biopharma to 35 kronor (33), reiterates hold" HC Wainwright, however, the other day lowers the target price for Hansa Biopharma to 103 kronor (111), reiterates buy.·20.2. · MuokattuThere are clearly shorters who are counting on a large capital increase and possibly a delayed or "missed" approval in the USA. HCW then believes that it will continue to run by the book and that we will have a US approval in 2026/2027 - hope HCW is right - otherwise the 2027 ski trip is screwed. Would like to see some kind of deal with something upfront, which could eliminate the risk of a capital increase. Even if it doesn't end with a capital increase, more loans would also be annoying - we need to become CashFlow positive - it's currently probably mostly the enormous burnrate that makes some people uncertain - and that's with good reason.·20.2.Of course, it would be nice if we avoid loans or capital increases, which, of course, take a part of our expected return on our investment. But I don't fear it so much in Hansa, which has good experience with directed issues to external investors. Last time, as far as I remember, at a price of 39.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 226 | - | - | ||
| 206 | - | - | ||
| 44 | - | - | ||
| 31 | - | - | ||
| 6 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 218 287 | 218 287 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 218 287 | 218 287 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 | ||
2025 Q1 -tulosraportti 24.4.2025 | ||
2024 Q4 -tulosraportti 6.2.2025 |
2025 Q4 -tulosraportti
26 päivää sitten
‧56 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 | ||
2025 Q1 -tulosraportti 24.4.2025 | ||
2024 Q4 -tulosraportti 6.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sitten• NovaQuest lock-up: Their 180-day lock-up from the issuance has expired, which means they can now freely sell their shares. • Motive for selling: NovaQuest has reasons to secure its capital, especially since their holding is in profit (subscription price 22 SEK). • Previous choice: In January, NovaQuest chose to receive cash payment instead of shares, which suggests that liquidity may be prioritized. • Market effect: If NovaQuest starts selling, this could push the share price down towards approximately 20 SEK, according to HS Formation. • Recent share sale: A close associate of Hansa Biopharma's board member Michael Bologna, Devin Holden (NovaQuest's compliance manager), has sold 141,000 shares for approximately 5.7 million SEK. Michael Bologna is Investment Manager at Novaquest Capital Management In short: The lock-up period is over, NovaQuest may have reason to sell to prioritize liquidity over ownership, and a recently registered insider sale could signal that more shares may come onto the market, which could negatively affect the price. It's a long wait until December 🕛 and perhaps the company has additional capital needs. My opinion and not advice. https://view.news.eu.nasdaq.com/view?id=b98b852aee40a178912c92e6a60a29fba&lang=sv&src=micro
- ·3 päivää sitten · MuokattuSomeone probably noticed the missing priority review on February 18th, I would think, when looking at the share price development. But it was not highlighted in the press at the time, so now we will briefly pay twice the share price loss for the delay. But what amount are we talking about in money for today's delayed focus on an "unexpected 4-month delay." 250 mio. SEK - divided by 100 mio. shares. 2.50 SEK per share, if the market doesn't come to its senses and realize that we - knowingly or unknowingly - already paid on February 19th. The amount largely corresponds to what the share often can rise on a good day - and fall on a bad day - without current share-related news. But currently the mood is not high in the stock market.
- ·5.3. · MuokattuCapital injection can happen in many ways. For example, through a directed issue, a loan, an affiliation with a partner, or a sale of licenses or an out-licensing of products with upfront milestone payments. The possibilities are many if the product is good, and there is interest in it, and the company has competent management. Fortunately, it absolutely doesn't have to be a rights issue, which usually goes terribly wrong. And Hansa has indeed had good success with directed issues previously. But it's a shame about the delay in any case.
- ·5.3. · MuokattuFOR THE RECORD: Many believe, quite wrongly, that the FDA review will take 12 months for Standard review, as Hansa Biopharma received for its BLA for imliffidase in kidney transplantation "HighDes). This compared to Priority review, where the review takes 6 months before PDUFA But here there is a misunderstanding among many! "The clock is ticking", i.e., the starting point for the review ("Review"), starts instead after day 60, given that the FDA accepts the BLA application for review. It is from this point that one counts 10 months (Standard review) and 6 months (Priority review) respectively. So 10 months counted from day 60, i.e., as of February 18, 2026, means that we land on a PDUFA-date as of December 19, 2026. Thus, one loses 4 months with Standard review, compared to if one had received Priority review. Not the end of the world, in other words! So a 4-month delay with Standard review ... compared to Priority review, i.e., 10 months of review instead of 6 months of the same ... is not, said again, the end of the world! Regards·3 päivää sitten · MuokattuI don't write on Facebook, but in a discussion forum, where the purpose hopefully is that we can all become wiser. After all, it's about our invested money. So, there will be no further comments on the above's offended reaction. The debate is more important than that, which can be seen, for example, by today's share price reaction and my post above in connection with it: "Need for further financing, you could have written. It's not certain that it has to happen as an emission - and many are scared by the word emission and read it as "rights issue" and think of the catastrophic rights issues one usually experiences - currently, for example, KD-ventures and Expres2ion, so therefore one must be careful with the words. The latest issues in Hansa have, on the contrary, been very good directed issues." Reply More
- ·19.2.DNB is really "showing off" today and significantly raises the target price: "DNB Carnegie raises the target price for Hansa Biopharma to 35 kronor (33), reiterates hold" HC Wainwright, however, the other day lowers the target price for Hansa Biopharma to 103 kronor (111), reiterates buy.·20.2. · MuokattuThere are clearly shorters who are counting on a large capital increase and possibly a delayed or "missed" approval in the USA. HCW then believes that it will continue to run by the book and that we will have a US approval in 2026/2027 - hope HCW is right - otherwise the 2027 ski trip is screwed. Would like to see some kind of deal with something upfront, which could eliminate the risk of a capital increase. Even if it doesn't end with a capital increase, more loans would also be annoying - we need to become CashFlow positive - it's currently probably mostly the enormous burnrate that makes some people uncertain - and that's with good reason.·20.2.Of course, it would be nice if we avoid loans or capital increases, which, of course, take a part of our expected return on our investment. But I don't fear it so much in Hansa, which has good experience with directed issues to external investors. Last time, as far as I remember, at a price of 39.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 226 | - | - | ||
| 206 | - | - | ||
| 44 | - | - | ||
| 31 | - | - | ||
| 6 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 218 287 | 218 287 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 218 287 | 218 287 | 0 | 0 |